1. Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma
- Author
-
Chen, Ru, Dawson, David W, Pan, Sheng, Ottenhof, Niki A, de Wilde, Roeland F, Wolfgang, Christopher L, May, Damon H, Crispin, David A, Lai, Lisa A, Lay, Anna R, Waghray, Meghna, Wang, Shouli, McIntosh, Martin W, Simeone, Diane M, Maitra, Anirban, and Brentnall, Teresa A more...
- Subjects
Rare Diseases ,Orphan Drug ,Cancer ,Digestive Diseases ,Pancreatic Cancer ,Aetiology ,2.1 Biological and endogenous factors ,Adenocarcinoma ,Carcinoma ,Pancreatic Ductal ,Cell Line ,Tumor ,Female ,Humans ,Male ,Middle Aged ,Neoplasm Proteins ,Pancreatic Neoplasms ,Proteomics ,Survival Analysis ,Clinical Sciences ,Pathology - Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with a dismal prognosis. However, while most patients die within the first year of diagnosis, very rarely, a few patients can survive for >10 years. Better understanding the molecular characteristics of the pancreatic adenocarcinomas from these very-long-term survivors (VLTS) may provide clues for personalized medicine and improve current pancreatic cancer treatment. To extend our previous investigation, we examined the proteomes of individual pancreas tumor tissues from a group of VLTS patients (survival ≥10 years) and short-term survival patients (STS, survival more...
- Published
- 2015